Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes

Table 2 Table of missing data

Month of study	no treatment		baseline	treatment
Month of study	0	1	2	3	4	5	6	7	8	9	10	11
Total number of patients included in analysis	71	93	98	97	90	86	83	72	50	45	31	27
Data not submitted	27	5	0	1	0	0	0	0	3	3	5	3
Ineffective (cumulative)	0	0	0	0	3	6	8	11	17	18	18	18
Side effects (cumulative)	0	0	0	0	3	4	4	5	5	5	5	5
Other reason (cumulative)	0	0	0	0	0	0	0	0	0	0	0	1
Ongoing treatment at time of analysis (cumulative)	0	0	0	0	2	2	3	10	23	27	39	44

Table accounting for missing data throughout the study period. Three months of baseline data (month 0, 1, 2) is followed by nine months of post-treatment data (month 3–11), when patients received monthly erenumab injections. The total number of patients included in the dataset for each month is shown at the top. This is broken down into the number of patients who failed to submit a questionnaire for each given month but remained in the analysis (‘data not submitted’), and cumulative discontinuation rates throughout the study period for various reasons (ineffectiveness, side effects, other (specifically, pregnancy). The final column shows the cumulative number of patients that were continuing to receive erenumab but had not completed sufficient months of treatment to provide data beyond a certain timepoint

ISSN: 1129-2377